Mounjaro was launched in India earlier this year, while many leading multinational pharma companies are in the race to ...

Novo Nordisk is likely to draw investor attention on Monday after the company said it is moving forward with the oral and ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

Higher dose of Wegovy ® provided average weight loss of 21% in people with obesity - with a third achieving 25% or more - according to data presented at ADA. Results from the phase 3b STEP UP trial ...

Novo Nordisk ( NVO 6.12%) stock, maker of the blockbuster GLP-1 agonist weight-loss drugs Ozempic and Wegovy, jumped a lucky 7% through 12:20 p.m. ET Tuesday after London's Financial Times reported ...

GLP-1 drugs like Ozempic help with weight loss, but how do they stack up against bariatric surgery? A new study breaks it ...

Novo Nordisk's Rybelsus, a daily pill with the same properties as Ozempic, was FDA-approved for diabetes in 2019. However, its weight loss results didn't stack up to other GLP-1 drugs in studies ...

In a late-stage clinical trial, Wegovy (semaglutide) significantly reduced liver inflammation and reversed scarring in people with the liver disease MASH. MASH is associated with obesity and type ...

In the STEP UP trial, the higher dose of Wegovy ® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to ...